DDInter528 DDInter1376
Dextropropoxyphene is an opioid analgesic manufactured by Eli Lilly and Company. It is used in the symptomatic treatment of mild pain. It displays antitussive and local anaesthetic actions. Due to the risk of cardiac arrhythmias and overdose, possibly leading to death, dextropropoxyphene has been withdrawn from the market in Europe and the United States. The drug is often referred to as the general form, "propoxyphene", however only the dextro-isomer (dextropropoxyphene) has any analgesic effect. The levo-isomer appears to exhibit a very limited antitussive effect.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Dextropropoxyphene {u} may lead to a major life threatening interaction when taken with {v} Tamoxifen
Dextropropoxyphene {u} (Compound) resembles {v} (Compound) Disopyramide
Dextropropoxyphene {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mepenzolate
Dextropropoxyphene {u} (Compound) resembles {v} (Compound) Levacetylmethadol
Dextropropoxyphene {u} (Compound) binds {v} (Gene) CYP3A7-CYP3A51P
Dextropropoxyphene {u} (Compound) upregulates {v} (Gene) UBQLN2
Dextropropoxyphene {u} (Compound) is included by {v} (Pharmacologic Class) Full Opioid Agonists
Dextropropoxyphene {u} (Compound) downregulates {v} (Gene) RUVBL1
Dextropropoxyphene {u} (Compound) causes {v} (Side Effect) Asthenia
Dextropropoxyphene {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Dextropropoxyphene may lead to a major life threatening interaction when taken with Tamoxifen
Dextropropoxyphene (Compound) resembles Disopyramide (Compound)
Dextropropoxyphene may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate
Dextropropoxyphene (Compound) resembles Levacetylmethadol (Compound)
Dextropropoxyphene (Compound) binds CYP3A7-CYP3A51P (Gene)
Dextropropoxyphene (Compound) upregulates UBQLN2 (Gene)
Dextropropoxyphene (Compound) is included by Full Opioid Agonists (Pharmacologic Class)
Dextropropoxyphene (Compound) downregulates RUVBL1 (Gene)
Dextropropoxyphene (Compound) causes Asthenia (Side Effect)
Dextropropoxyphene may cause a minor interaction that can limit clinical effects when taken with Metronidazole